Enrolling Women into HIV Preventive Vaccine Trials: An Ethical Imperative but a Logistical Challenge

摘要

With almost 5 million new HIV infections and 3 million deaths from AIDS occurring every year worldwide, the development of a safe, effective, and accessible HIV vaccine has become one of the most urgent global public health needs. The United Nations estimates that 17.5 million women between the ages of 15 and 49 years are living with HIV, accounting for nearly half of the 40.3 million infections worldwide [1]. These figures reveal the increasingly female face of AIDS.